phase 2
study 1
frontline 1
brentuximab 1
vedotin 1
monotherapy 1
hodgkin 1
lymphoma 1
patients 2
aged 1
years 1
older 1
trial 1
carfilzomib 1
pr 1
combination 1
vorinostat 1
saha 1
relapsed 1
refractory 1
bcell 1
lymphomas 1
